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linical and Angiographic Risk Assessment
n Patients With Left Main Stem Lesions
cot Garg, MB, CHB,* Gregg W. Stone, MD, PHD,‡ Arie-Peter Kappetein, MD, PHD,†
oseph F. Sabik III, MD,§ Charles Simonton, MD, Patrick W. Serruys, MD, PHD*
otterdam, the Netherlands; New York, New York; Cleveland, Ohio; and Santa Clara, California
ercutaneous coronary intervention of unprotected left main stem lesions has been shown to be a suitable
lternative to cardiac surgery in selected patients, emphasizing the need for appropriate risk stratiﬁcation
rior to selection of revascularization modality. Several risk models based on clinical and angiographic variables
ave been developed to guide patient selection, each of which has signiﬁcant limitations. This paper reviews
ontemporary and newly proposed risk models for patients undergoing left main stem revascularization.
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Phe left main stem is rarely longer than 15 mm,
ut in view of its extensive myocardial distribution,
t is a vitally important part of the coronary arterial
ree. Unprotected left main stem (ULM) lesions
arry the worst prognosis of any coronary lesion,
ainly because of the extensive amount myocar-
ium placed at jeopardy by such lesions. The
ortality for nonrevascularized ULM disease has
een reported to be as high as 37% at 3 years (1).
he optimal therapy for patients with ULM dis-
ase remains the subject of continuing debate (2,3).
Coronary artery bypass grafting (CABG) was es-
ablished as the gold standard for treatment of pa-
ients with ULM disease on the basis of trials that
andomly assigned patients to CABG versus medical
herapy (4). Historically, patients with ULM disease
ave been excluded from randomized trials compar-
ng percutaneous coronary intervention (PCI) to
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anuscript follows a similarly titled presentation given by Patrick W.
erruys at the American College of Cardiology meeting in Atlanta 2010.banuscript received May 24, 2010, accepted June 11, 2010.ABG (5,6). Nevertheless, surveys of real-world
ractice have indicated that approximately one-third of
atients with ULM lesions are treated by PCI (7).
ercutaneous coronary intervention for ULM disease
s usually “accepted” when: 1) patients require bailout
LM PCI following complications during PCI;
) ULM disease occurs in the setting of acute
yocardial infarction (MI); 3) the left main is
rotected by a functional coronary bypass graft;
) patients are turned down for CABG; or 5) patients
efuse surgery. Less settled are the indications for
eft main PCI in patients who are good candidates
or CABG.
Recently, important studies have been published
pecifically relating to selection of revascularization
odalities of the ULM (8). These data suggest that
n certain groups of patients with ULM disease, such
s those with ostial or shaft lesions, revascularization
ith PCI remains a valid alternative therapy to
ABG (8–10). Consequently, in the recent focused
pdate from the American College of Cardiology/
merican Heart Association (ACC/AHA), PCI for
LM lesions has been upgraded from a Class III to
Class IIb indication in those patients with “anatom-
cal conditions which are associated with a low risk
rom PCI procedural complications and clinical con-
itions which predict adverse surgical outcomes” (11).
In view of this recommendation, there is now a
lear need to appropriately identify which patients
ith ULM should undergo revascularization with
CI or CABG. This highly relevant topic was
riefly touched upon in a recent white paper on
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892CI for ULM (8); however, its importance to everyday
linical practice necessitates a more detailed review. The aim
f this paper is to review the currently available methods for
isk stratifying those patients with ULM lesions requiring
evascularization.
oes the ULM Need Revascularization?
rior to embarking on the assessment of risk and formula-
ion of a revascularization strategy for patients with an
ngiographically identified ULM lesion, it is important to
determine whether the lesion is
in actual need of revasculariza-
tion (i.e., is hemodynamically
significant). The anatomic loca-
tion of the ULM, together with
vessel foreshortening and over-
lap makes angiographic visual-
ization and accurate lesion as-
sessment notoriously difficult.
Specifically, ostial left main le-
sions may appear more signifi-
cant than they truly are due to
catheter-induced artifacts, and
the severity of distal bifurcation
lesions may be notoriously diffi-
cult to accurately delineate. In
part due to these reasons, lesions
in the left main stem are subject
to the greatest degree of angio-
graphic intraobserver and inter-
observer variability compared
with lesions located elsewhere in
the coronary tree (12,13). Im-
portantly, studies have shown a
favorable prognosis in patients
with ULM lesions that are not
functionally significant (14).
Conversely, bypass grafts placed
to nonhemodynamically signifi-
cant lesions have a high rate of
early failure (15). Therefore, in
practice, a suspicious or borderline
ULM lesion warrants further
valuation with intravascular ultrasound, coronary computed
omography, and/or functional assessment with fractional flow
eserve (12,14,16), before either suggesting the need for revas-
ularization or dismissing the need altogether.
s There a Need for Risk Stratification
n ULM Revascularization?
n assessment of procedural risk is imperative once the
bbreviations
nd Acronyms
CC  American College of
ardiology
CEF  Age, Creatinine,
jection Fraction
HA  American Heart
ssociation
ABG  coronary artery
ypass grafting
SS  clinical SYNTAX
core
uroSCORE  European
ystem for Cardiac Operative
isk Evaluation
RC  Global Risk
lassification
ACCE  major adverse
ardiovascular and
erebrovascular events
ACE  major adverse
ardiac events
CRS  Mayo Clinic risk
core
I  myocardial infarction
CI  percutaneous
oronary intervention
TS  Society of Thoracic
urgery
Xscore  SYNTAX score
LM  unprotected left
ain stemecision has been made that revascularization of the ULM ds required. Technological advances, such as the availability
f left ventricular assist devices during high-risk cases (17),
ave increased the number of patients in whom PCI is now
easible; however, the appropriateness of ULM intervention
annot be considered without a proper assessment of the
isk and benefits of both PCI and CABG.
Procedural risk stratification (for both PCI and CABG)
erves several purposes. In the short term, it provides clinicians
ith supplementary information that can help guide treatment
trategy, particularly in view of the latest guidelines “allowing,”
ith a Class IIb recommendation, ULM PCI only in cases in
hich procedural success is high and procedural risk is low. In
ddition, and perhaps most importantly, procedural risk strat-
fication enables patients to be more adequately informed about
he risks/benefits of the alternative revascularization strategies
vailable, allowing them to make an informed decision. Ulti-
ately, it is the duty of a clinician to convey full and
nderstandable information to their patients (18). Contrary to
opular belief, after being offered CABG, very few patients
ctually refuse. In the SYNTAX (Synergy Between Percuta-
eous Coronary Intervention With TAXUS and Cardiac
urgery) trial, the rate of refusal was 0.4% (9). Surgeons raise
he valid concern that patients who refuse CABG may not
ave had the opportunity to discuss matters with a surgeon and
ay have been swayed in their decision by a relatively 1-sided
iscussion (1). Good clinical practice should ensure that
atients with significant ULM disease have the opportunity to
peak to both a cardiac surgeon and interventional cardiologist
ogether (the “Heart Team,” often with a noninvasive cardiol-
gist) to enable an interactive discussion wherein all issues are
iscussed and addressed (1). With the current state of evidence,
d hoc ULM PCI should not be performed in the stable
atient.
Risk stratification models, and collections of decisions re-
ulting from patient-physician discussions, provide a vital
easure of patient care and may identify future directions to
urther improve outcomes. In terms of clinical governance and
he public reporting of results, risk stratification is imperative to
nable a suitable comparison of performance between clinicians
nd government standards. Their significance is further en-
anced as it becomes increasingly essential for clinicians to be
ble to justify clinical decisions to patients, peers, and regula-
ory bodies.
hat Methods of Risk Stratification Are
vailable for Patients With ULM Lesions?
variety of different methods of stratifying risk in patients
ndergoing ULM revascularization is available; however,
ach has been applied to different study populations, limit-
ng the comparisons that can be made among different risk
odels. In essence, risk models can be divided into those
sing clinical-based variables, those using angiographic
ata, and those using a combination of both. Table 1
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893ummarizes various contemporary risk models that are
escribed in more detail herein.
linical-Based Scores
hese risk scores only incorporate clinical variables and do
ot require any data from the angiogram. They offer the
dvantage of being able to be computed relatively quickly,
sually at the bedside, and principally include variables that
re not subject to user interpretation, thereby ensuring
xcellent reproducibility.
Table 1. Summary of Contemporary and Newly Developed Risk Models for
Risk Model
Number of Variables
Calculate Sco
Clinical A
EuroSCORE (9,19–28) 17
Mayo Clinic Risk Score (30–32) 17
ACEF (33) 3
AHA/ACC lesion classiﬁcation (36–38,40) 0 1
SYNTAX score (6,9,24,26,34,39–48) 0 1
Society of Thoracic Surgery score (31,49–51) 40
Clinical SYNTAX score (52) 3 1
Global Risk Classiﬁcation (54) 17 1
AHA/ACC  American Heart Association/American College of Cardiology; ACEF  Age, Creatinine
Cardiac Operative Risk Evaluation; PCI percutaneous coronary intervention; SYNTAX Synergy be
stem.
Table 2. The Additive EuroSCORE
Patient characteristics
Age Per 5 years or part thereof over the age of 60 ye
Sex Female
Chronic pulmonary disease Long-term use of bronchodilators or steroids for
Peripheral arteriopathy *Claudication, carotid stenosis 50%, previous o
Neurological dysfunction Severely affected mobility or day-to-day function
Previous cardiac surgery Previous opening of the pericardium
Serum creatinine Pre-operatively 200 mol/l
Active endocarditis Antibiotic therapy at time of surgery
Critical pre-operative state *Pre-operative cardiac arrest, ventilation, renal fa
Cardiac-related factors
Unstable angina Rest pain requiring IV nitrates
Left ventricular function Moderate (30%–50%)
Poor (30%)
Recent MI Within 90 days
Pulmonary hypertension Systolic pulmonary pressure 60 mm Hg
Operation-related factors
Emergency Operation performed before the start of next wo
Other than isolated CABG Major cardiac procedure other than or in additio
Surgery on thoracic aorta
Post-infarct septal rupture
The additive EuroSCORE is calculated by summating the individual score from 17 different variableIV intravenous; MImyocardial infarction; other abbreviations as in Table 1.uroSCORE. The European System for Cardiac Operative
isk Evaluation (EuroSCORE) (19) is an additive clin-
cal score, calculated using 17 different objective clinical
ariables (Table 2), which has been used since 1999 to
redict in-hospital mortality in patients undergoing car-
iac surgery (19). Subsequent studies have confirmed the
bility of the EuroSCORE to also predict long-term
ortality (20 –22).
There have been no dedicated studies of the EuroSCORE
additive or logistic) in patients with isolated ULM lesions
sment of Risk in Patients Undergoing Revascularization
to
Validated in PCI/CABG
Specific Evaluation
in ULM Patients?raphic PCI CABG
  
  –
–  –
lesion)  – 
lesion)   
–  –
lesion)  – –
lesion)   
n Fraction; CABG  coronary artery bypass grafting surgery; EuroSCORE  European System for
Percutaneous Coronary Interventionwith Taxus and Cardiac Surgery; ULM unprotected leftmain
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894ndergoing surgical revascularization. However, the initial
alidation of these scores utilized a large patient database,
hich included over 4,000 (22%) patients with a ULM
esion (19,23), thereby indirectly confirming the utility of
he EuroSCORE in the assessment of patients undergoing
ABG for ULM disease.
The utility of using the EuroSCORE in patients under-
oing PCI has been assessed in the multicenter randomized
YNTAX study (9,24) and several additional nonrandom-
zed studies (25–28). Four of these studies specifically
valuated the EuroSCORE in patients with ULM disease
24–27), with most except the study by Kim et al. (27)
ncluding a surgical treatment arm for the comparison of
utcomes.
All studies have identified the additive EuroSCORE as
n independent predictor of major adverse cardiovascular
nd cerebrovascular events (MACCE) in patients with
LM disease undergoing PCI (24–27). In addition, all
tudies that include a surgical control group have reported
hat the additive EuroSCORE is an independent predictor
f MACCE for patients with a ULM lesion undergoing
ABG (24–26). In the left main stem subgroup of the
YNTAX study, the additive EuroSCORE was shown to
e an independent predictor of MACCE at 1-year
ollow-up irrespective of the method of revascularization
odds ratio [OR]: 1.21; 95% confidence interval [CI]: 1.12
o 1.32; p  0.001) (24). Rodés-Cabau et al. (25) reported
imilar results among 249 octogenarians with ULM disease,
ith a EuroSCORE 9 identified as the best predictor of
ACCE after PCI and CABG out to a mean of 23 months
f follow-up (25). The C-statistic for the ability of the
uroSCORE to predict MACCE was reported as 0.65.
ore recently, retrospective analysis of the large MAIN
OMPARE (Revascularization for Unprotected Left Main
oronary Artery Stenosis: Comparison of Percutaneous
oronary Angioplasty versus Surgical Revascularization
rom Multicenter Registry), which included 1,580 patients
ith ULM, demonstrated that the additive EuroSCORE
as an independent predictor of death/MI/stroke in pa-
ients having PCI or CABG out to 3-year follow-up (26).
In a study without a comparative surgical arm, Kim et al.
27) evaluated the potential of the EuroSCORE in 324
atients undergoing PCI for ULM disease, at a median of
6.3 months of follow-up. A EuroSCORE 5, commonly
ccepted as a high-risk surgical group (19), was shown to be
n independent predictor of death/MI (hazard ratio [HR]:
.4; p  0.02), with a C-statistic for the ability of the
uroSCORE to predict death/MI of 0.61. In contrast,
omagnoli et al. (28) reported a C-statistic of 0.91 for the
rediction of in-hospital mortality using the EuroSCORE.
he superior C-statistic in this report (28) may be attrib-
ted to Romagnoli et al. limiting outcome measures to only
he hard end point of mortality and restricting the period of aollow-up to only in-hospital events. Of note, the C-statistic
ell to 0.56 when assessing procedural failure.
Concerns that the additive EuroSCORE underestimated
isk in surgical patients deemed to be at the highest risk (29)
ed to the development of the logistic EuroSCORE. In the
etting of PCI, only Romagnoli et al. (28) have assessed the
erformance of the logistic EuroSCORE, which was sub-
equently shown to have a predictive ability that was similar
o the additive EuroSCORE.
In summary, the limited studies that have assessed the
dditive EuroSCORE in patients with ULM disease sug-
est that the EuroSCORE in isolation is probably of little
se in determining selection of revascularization strategy, as
atients with high EuroSCORE have a high risk of adverse
vents following either PCI or CABG. Nevertheless, it is
lear that the EuroSCORE is an effective method of
dentifying which patients, treated with PCI or CABG, are
t high risk of mortality and/or MACCE. The role of the
ogistic EuroSCORE is as yet undetermined.
ayo Clinic risk score. The Mayo Clinic risk score (MCRS)
ses a mixture of 7 clinical variables to predict in-hospital
ortality after revascularization with either PCI or CABG
Table 3). The MCRS has been validated in patients having
CI and CABG (30,31); however, no studies have been
erformed specifically in patients with ULM lesions. The
nly study to report the MCRS and specify the number of
atients with a ULM lesion enrolled only 96 ULM patients,
omprising 1.3% of the overall study cohort (32). This small
roup is clearly insufficient to allow extrapolation of the
verall study results to patients with ULM disease in
eneral. Therefore, the utility of using the MCRS for either
uantifying procedural risk and/or selecting revasculariza-
ion strategy in patients with ULM disease remains cur-
ently undefined.
CEF score. The Age, Creatinine, Ejection Fraction
ACEF) score (33) is calculated using the formula [patient
ge  ejection fraction (%)]  [1 if creatinine 2 mg/dl].
he only published data at present relate to patients
ndergoing elective CABG, where the ACEF score was
hown to have a similar accuracy and calibration for in-
ospital mortality compared with other more complicated
urgical risk scores such as the EuroSCORE and the
leveland Clinic Score. The development and validation of
his score included 8,648 patients; however, the proportion
f patients with a ULM lesion was not specified. Further-
ore, as with the MCRS, the value of the ACEF score in
ither determining revascularization strategy and/or proce-
ural risk in patients undergoing PCI is as yet undetermined
y virtue of the lack of any data in PCI patients. Ultimately,
he role of the ACEF score in the assessment of patients
ith ULM disease requires further investigation.
In summary, the different clinical-based risk scores have
een found to be useful in predicting early and late mortality
nd MACCE in patients undergoing PCI and/or CABG.
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895owever, no clinical-based score has been demonstrated to
iscriminate the relative early procedural risk or late survival
etween PCI and CABG.
ngiographic-Based Scores
everal angiographic-based scores have been proposed that
re independent of patient clinical variables, being calcu-
ated using only angiographic data. This has obvious impli-
ations for the timing of risk stratification. More impor-
antly, however, the intervariability inherent in angiographic
ssessment introduces a subjective element to the assess-
ent of risk when using angiographic-based scores (34,35).
CC/AHA lesion classiﬁcation. The ACC/AHA lesion clas-
ification was 1 of the original angiographic scoring systems;
t was first devised in 1986 and modified in 1990. The
urrent scoring system uses 11 angiographic variables to
ategorize lesions into types A, B1, B2, and C. Historical
tudies prior to the arrival of drug-eluting stents indicated
hat that ACC/AHA lesion classification did have a prog-
ostic impact on early and late outcomes (36,37). Data in
ontemporary practice using drug-eluting stents, however,
re limited to retrospective registries. The German Cypher
egistry enrolled over 6,700 patients with approximately
,000 lesions, 200 of which were ULM lesions. Results
ndicated the lack of any relationship between ACC/AHA
esion classification and clinical outcomes out to 6-month
ollow-up (38). In contrast to these results, a significant
elationship between the ACC/AHA lesion score (derived
y assigning 1, 2, 3, and 4 points to types A, B1, B2, and C
esions, respectively) and clinical outcomes has been dem-
nstrated in patients with 3-vessel- (39) or ULM-disease
40) undergoing PCI. Specifically, Capodanno et al. (40)
emonstrated that the ACC/AHA lesion score significantly
Table 3. The Mayo Clinic Risk Score
Variable
Age, yrs
Creatinine, mg/dl
Left ventricular ejection fraction, %
Pre-procedural shock
Myocardial infarction 24 h
Congestive heart failure on presentation (without acute MI or shock)
Peripheral vascular disease
The Mayo Clinic risk score is calculated using data from 7 individual variables, each of which have th
Abbreviations as in Table 2.redicted both cardiac death (p  0.001) and major adverse tardiac events (MACE) (p  0.02) at 1-year follow-up
mong 255 patients with ULM undergoing PCI with
rug-eluting stents. Moreover, in this study, the ACC/
HA lesion score was found to be an independent predictor
f cardiac death, but not MACE.
YNTAX score. The SYNTAX score (SXscore) is a well-
escribed anatomical scoring system that enables quantification
f the complexity of coronary anatomy (34,41). Lesion location
nd adverse lesion characteristics are used to calculate the score
sing either a downloadable calculator or the SXscore website
42) (Table 4). The SXscore was first used prospectively in the
YNTAX trial and has since been calculated in a number of
ifferent clinical trials both in elective and acute patients, with
imple or complex disease, followed up for between 1 and 5
ears (6,9,34,39–41,43–46). In all studies, irrespective of
ollow-up duration, a higher SXscore tertile has consistently
een associated with the poorest outcomes (6,9,39,40,43–46),
hereas several studies also identified the SXscore as an
ndependent predictor of MACE in patients undergoing PCI
6,39,40,43,44).
The value of the SXscore in patients with ULM disease
as been specifically assessed in over 3,000 patients with
ollow-up between 12 months and 4 years in 4 separate
tudies: specifically, the 705-patient ULM subgroup of the
YNTAX trial (24,47), the CUSTOMIZE registry (ap-
raise a CUSTOMIZED strategy for left main revascular-
zation) (n 819) (40,43), the MAIN COMPARE registry
n  1,580) (26), and the Rotterdam LM (Rotterdam Left
ain) registry (n  148) (44). Importantly, a surgical arm
as included in all but the Rotterdam LM registry, thereby
llowing investigation as to the role of the SXscore for
electing revascularization strategy and/or determining pro-
edural risk.
The ULM subgroup of the SYNTAX study represents
Points
See below
See below
See below
9
4
3
2
weighted score (30).eir ownhe only prospectively recruited ULM patient group
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89624,47). The rate of MACCE out to 2-year follow-up,
ogether with the individual components of death, stroke,
I, and repeat revascularization in patients randomly as-
igned to treatment with PCI or CABG, stratified accord-
ng to SXscore tertiles are shown in Table 5. Of note,
hereas the SXscore was an independent predictor of
ACCE for patients undergoing PCI, the same was not
rue for those undergoing CABG. This is not surprising
onsidering the bypass anastomosis occurs distal to the com-
lex disease. Moreover, the relatively “flat” relationship be-
ween MACCE and SXscore in patients undergoing CABG,
hich contrasts with the positive relationship between
ACCE and SXscore in patients undergoing PCI (Fig. 1),
ndicates how the SXscore, in addition to its ability to predict
utcomes, is able to aid revascularization decisions in these
atients. In those patients in the low and intermediate SXscore
ertiles, the rates of MACCE between PCI and CABG are
omparable (Table 5), whereas in those patients in the highest
Xscore tertile, outcomes are significantly worse in those
eceiving PCI.
Similar findings have been demonstrated in retrospective
egistries of patients undergoing ULM PCI who have
eported outcomes from 1 to 4 years of follow-up.
At 1-year follow-up, among 255 patients in the
Table 4. The SYNTAX Score Algorithm
1. Arterial dominance
2. Arterial segments involved per lesion
Lesion characteristics
3. Total occlusion
i. Number of segments involved
ii. Age of the total occlusion (3 months)
iii. Blunt stump
iv. Bridging collaterals
v. First segment beyond the occlusion visible by antegrade or
retrograde ﬁlling
vi. Side branch involvement
4. Trifurcation
i. Number of segments diseased
5. Bifurcation
i. Medina type
ii. Angulation between the distal main vessel and the side branch 70o
6. Aorto-ostial lesion
7. Severe tortuosity
8. Length 20 mm
9. Heavy calciﬁcation
10. Thrombus
11. Diffuse disease/small vessels
i. Number of segments with diffuse disease/small vessels
The SYNTAX score is calculated using this algorithm, which is applied to each individual coronary
lesion thathas adiameter stenosis greater than50%and is located inavessel that is larger than1.5
mm in diameter (41). The individual lesion scores are added together to give the final SYNTAX
score.USTOMIZE registry, the SXscore was identified as anndependent predictor of MACE (adjusted HR: 1.06; 95%
I: 1.02 to 1.10; p  0.005) and cardiac death (adjusted
R: 1.15; 95% CI: 1.05 to 1.26; p 0.003), with respective
-statistics of 0.64 and 0.83 (40). At 2-year follow-up,
urther analysis of the same registry (expanded to 819
atients) reaffirmed the ability of the SXscore to aid revas-
ularization decisions (43). The rate of MACE among
atients treated with PCI and CABG for those with an
Xscore 34 was 8.1% and 6.2% (p  0.46), respectively,
ompared with 32.7% and 8.5% (p  0.001) for those with
Xscore 34.
At 3-year follow-up in the MAIN COMPARE registry,
he rate of death/stroke/MI after ULM PCI increased from
.6%, to 9.4% and 11.4% with increasing SXscore tertile
p  0.01) (26). A significant trend was not present,
owever, when rates of MACCE (composite of death,
troke, MI, and repeat revascularization) were stratified
ccording to SXscore; of note, this population included
atients treated with bare-metal stents, which may in part
xplain this finding. Finally, data from the Rotterdam LM
egistry indicate that the ability of the SXscore to identify
hose at high risk of adverse outcomes following ULM
CI is sustained out to at least the 4-year follow-up (44).
In contrast to these studies, which have all consistently
emonstrated no interaction between the SXscore and those
Table 5. 2-Year Outcomes in the Left Main Subgroup of the SYNTAX Trial
Stratified by SYNTAX Score Tertiles
2-Year Outcomes (47)
Treatment Modality
p ValuePCI (%) CABG (%)
Low SYNTAX score tertile (0–22) n  118 n  104
Major adverse cardiovascular events 15.5 18.8 0.45
Death 0.9 4.9 0.07
Stroke 0.9 4.1 0.12
MI 3.6 2.0 0.53
Death/stroke/MI 4.5 9.9 0.10
Repeat revascularization 14.7 10.1 0.37
Intermediate SYNTAX score tertile (23–32) n  103 n  92
Major adverse cardiovascular events 22.4 22.4 0.91
Death 4.9 11.3 0.10
Stroke 1.0 2.3 0.46
MI 4.0 3.3 0.86
Death/stroke/MI 9.8 14.5 0.28
Repeat revascularization 14.9 12.8 0.72
High SYNTAX score tertile (33) n  135 n  150
Major adverse cardiovascular events 29.7 17.8 0.02
Death 10.4 4.1 0.04
Stroke 0.8 4.2 0.08
MI 8.4 6.1 0.48
Death/stroke/MI 15.6 11.5 0.32
Repeat revascularization 21.8 9.2 0.003Abbreviations as in Tables 1 and 2.
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897ndergoing CABG, are the results of a study by Birim et al.
48) who reported surgical outcomes in 148 patients with
LM disease stratified according to tertiles. The study,
hich only used 1 investigator to score all angiograms,
emonstrated that the SXscore was an independent predic-
or of MACCE at 1-year follow-up after CABG. The small
ample size and retrospective design may have influenced
he results, which have not yet been repeated, or fully
xplained (48).
Both Valgimigli et al. (39) and Capodanno et al. (40)
ave reported a significant correlation between the SXscore
ith the ACC/AHA lesion score. However, the SXscore
as been shown to have superior discriminative ability
ompared with the ACC/AHA lesion score for both cardiac
eath (SXscore 0.83 vs. 0.76 ACC/AHA) (40) and
ACCE (SXscore 0.73 vs. ACC/AHA 0.56) (39).
Overall, these multiple studies indicate that the SXscore
as a role to play in both stratifying clinical outcomes and
ssisting important revascularization decisions in those pa-
ients undergoing revascularization of ULM disease.
Figure 1. Clinical Outcomes (Composite of Death, Stroke, MI and Repeat
Revascularization) Stratified by SYNTAX Score Tertile
Clinical outcomes (composite of death, stroke, myocardial infarction, and
repeat revascularization) stratiﬁed by SYNTAX score tertile among the 705
patients randomized to treatment with percutaneous coronary intervention
(PCI) or coronary artery bypass graft surgery in the unprotect left main sub-
group of the SYNTAX (Synergy between Percutaneous Coronary Interven-
tion with Taxus and Cardiac Surgery) study (47). There is an increasing
event rate among patients treated with percutaneous coronary intervention
with increasing SYNTAX score tertile. Conversely, there is relatively little
difference between outcomes in the coronary artery bypass grafting group.
These results illustrate the utility of the SYNTAX score in determining revas-
cularization strategy. CABG  coronary artery bypass grafting; MI  myo-
cardial infarction.
Table 6. The Clinical SYNTAX Score
Clinical SYNTAX Score  SYNTAX Score   AgeLV ejection fraction
The clinical SYNTAX score is calculated using the patient’s age, left ventricular ejection fraction, seruLV left ventricular; other abbreviations as in Table 1.ombined Risk Scores
he clinical and angiographic-based scores assess com-
letely different, but equally important, variables. Impor-
antly, clinical and angiographic risk models may be better
uited to predict different outcomes. For example, Singh et
l. (32) reported that the MCRS was superior to the
CC/AHA lesion classification in the prediction of death/
troke/MI/emergent CABG, but inferior for the prediction
f angiographic failure. This observation supports the no-
ion of a model combining clinical and angiographic vari-
bles, which intuitively would be able to provide a more
omplete assessment of risk. In view of this, several
ombined clinical and angiographic risk scores have been
eveloped. However, validation of these scores is at an
arly stage, such that outcome data are currently confined
o small, retrospective studies, with limited follow-up.
he most prominent combined risk scores include: So-
iety of Thoracic Surgery (STS) Score, clinical SYNTAX score
CSS), and combined EuroSCORE and SYNTAX.
TS Score. The STS score is considered a combined risk
core, although it only incorporates 2 angiographic variables
presence of ULM lesion and number of vessels diseased)
ogether with 40 clinical variables. The STS risk model
redicts the risk of operative mortality and morbidity after
dult cardiac surgery (49,50) such that it is used exclusively
y cardiac surgeons; at present, no data exist regarding the
tility of the STS score in patients undergoing PCI.
revious data have indicated the STS score to be superior to
he MCRS in patients having CABG (31), whereas com-
arisons between the EuroSCORE and STS score indicate
nly a slight improvement in mortality prediction with the
TS score (51). There appears to be little role of the STS
core in the assessment of patients with ULM disease prior
o the selection of a strategy of surgical revascularization.
linical SYNTAX score. The notion of adding a clinical-
ased component to the angiographic SXscore led to the
evelopment of the CSS (52). This score incorporates, as its
linical component, the ACEF score, which is modified to
nclude the creatinine clearance as opposed to the serum
reatinine as originally described by Ranucci et al. (33). This
as performed to improve the discrimination of risk as
reviously observed when a similar modification was incor-
orated into the EuroSCORE (53). The CSS is calculated
y multiplying the SXscore with this modified ACEF score
Table 6). The evaluation of the CSS has only been
erformed thus far in 1 patient study cohort, which included
1 point for each 10-ml creatinine clearance* 60 ml/min/1.73 mm2
tinine clearance, and SYNTAX score (52). Calculated using the Cockcroft/Gault equation.%

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898atients with multivessel disease but excluded those with
LM lesions. At 5-year follow-up, among patients with
riple-vessel disease, the CSS was shown to have a superior
iscriminative ability compared with the SXscore and ACEF
core in the prediction of both mortality (CSS 0.80 vs. SXscore
.70 vs. ACEF 0.73) and MACCE (CSS 0.67 vs. SXscore
.64 vs. ACEF 0.59) (52). Further evaluation of this score is
equired, particularly in patients with ULM disease.
uroSCORE and SYNTAX. The previous discussion has indi-
ated that the EuroSCORE and SXscore are the most
Figure 2. The Relationship Between the EuroSCORE and the SYNTAX Scor
All patients with a EuroSCORE (European System for Cardiac Operative Risk Ev
spective of the treatment modality or their SYNTAX score tertile. Furthermore,
above and below 4 occurs in patients in the intermediate SYNTAX score tertile
score tertile when treated with coronary artery bypass grafting. ULM  unprotalidated tools for risk assessing patients undergoing coro- bary revascularization and in particular those with ULM
isease. The combination of these 2 scores appears partic-
larly attractive given the ability of the EuroSCORE to
dentify patients at high risk of adverse events irrespective of
reatment modality and the ability of the SXscore to assist in
stablishing optimal revascularization strategy.
The 2 scores have a somewhat complex relationship that
s highlighted by the confusing results seen in the SYNTAX
tudy, when patients in low, intermediate, and high SXscore
ertiles were further subdivided by a EuroSCORE above or
ssessed in the ULM Population Enrolled in the SYNTAX Study
n) 4 have a greater event rate than patients with a EuroSCORE 4 irre-
rgest absolute difference in event rate between patients with a EuroSCORE
treated with percutaneous coronary intervention, and in the lowest SYNTAX
left main stem; other abbreviations as in Figure 1.e as A
aluatio
the la
whenelow the median of 4 (Fig. 2). The EuroSCORE was an
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899ndependent predictor of MACCE for both revasculariza-
ion strategies; therefore it would have been expected that
utcomes in those with a high EuroSCORE were worse
han those with a low EuroSCORE irrespective of the
Xscore tertile. However, as is clearly seen, in the low
Xscore tertile the division by EuroSCORE identified
hose patients at highest risk of events from surgery and had
ittle effect on PCI outcomes. In the high SXscore tertile
roup the opposite was observed: whereas surgical outcomes
n patients with a EuroSCORE above or below 4 were
imilar, PCI outcomes varied from 20% to 35%. The small
umber of patients in these subgroups may certainly have
layed its part in these observations, which therefore require
urther investigation with subsequent larger studies.
Although the subdivision of patients into 2 groups
ccording to their EuroSCORE produced puzzling results,
ore promising results have been reported by Capodanno et
l. (54) when subdividing the EuroSCORE into the histor-
cally defined groups of low (0 to 2), intermediate (3 to 5),
nd high risk (6) and combining this in a Global Risk
lassification (GRC) with SXscores in low, intermediate,
nd high tertiles (Table 7). This GRC has so far only been
pplied to a population of 255 patients undergoing ULM
evascularization, for which SXscores were calculated retro-
pectively. At 2-year follow-up, the rates of cardiac death in
atients in low, intermediate, and high SXscores tertiles
ere 3.9%, 5.4%, and 21.9%, whereas with the GRC, rates
f 1.6%, 16.0%, and 31.4% were seen in low, intermediate,
nd high GRC groups. Additional results indicated that the
RC had a greater discriminatory ability when compared
ith other risk scores, including the EuroSCORE and the
Table 7. The Global Risk Classification
EuroSCORE
SYNTAX Score Tertile
LOW INTERMEDIATE HIGH
LOW Low Low Intermediate
MEDIUM Low Low Intermediate
HIGH Intermediate Intermediate High
The Global Risk Classification uses the patient’s EuroSCORE and SYNTAX score in combination to
classify patients as low, intermediate, or high risk (54). It is derived using this matrix.
Abbreviations as in Table 1.
Table 8. Comparison of the Different Predictive Ability of Risk Models Whe
Risk Score Study Hard End Point (Follow-Up)
EuroSCORE Romagnoli et al. (28) Mortality (In-hospital)
Mayo Clinic Risk Score Singh et al. (32) Death/stroke/MI/emergent CABG (In-h
AHA/ACC lesion score Capodanno et al. (40) Cardiac death (12 months)
SYNTAX score Capodanno et al. (40) Cardiac death (12 months)
Clinical SYNTAX score Garg et al. (52) All-cause death (60 months)TLR target lesion revascularization; other abbreviations as in Table 1.Xscore, for the prediction of in-hospital and 2-year mor-
ality. In essence, the study reiterated the importance of
onsidering both clinical and angiographic variables in the
ssessment of overall risk and provided a combined scoring
ystem that appears to hold promise; however, validation in
large patient group is required.
imitations of Risk Models
here are numerous other variables such as diabetic status
nd body mass index, which have been shown to influence
linical outcomes but have not been included in most risk
odels. Importantly, the number of variables included in
he risk model must be sufficient, on one hand, to ensure the
odel adequately predicts risk, but, on the other hand, the
umber must not be excessive to inhibit user uptake.
urthermore, inclusion of numerous variables increases the
hances of colinearity between independent variables result-
ng in redundant information being collected (33), whereas
lso increasing the chances of overfitting the model, thereby
educing the overall accuracy of the results (55). Overall, it
ust be acknowledged that all risk scores lack the sensitivity
o accurately predict events in an individual patient who may
ave comorbidities not accounted for in the risk model. The
urpose of risk scores therefore is to report the risk of the
opulation being studied; in a good risk model the variables
elected will account for interpatient variation in comorbidities.
The accuracy of risk models can also be improved with
he inclusion of treatment-specific procedural factors,
uch as the number of stents implanted and the stenting
echnique employed in patients having PCI, and the
ardiopulmonary bypass time and use of off-pump surgery
n patients having CABG. For example, Chen et al. (56)
ncorporated 4 procedural variables together with 17
linical and 33 angiographic variables to produce a risk
odel that had a greater predictive accuracy than the
Xscore alone in 337 patients with ULM disease treated
ith PCI. Despite the improved accuracy, it is important
o remember that these variables cannot be reliably
redicted prior to undertaking PCI or CABG, and
herefore their inclusion unfortunately moves the ability
o accurately calculate risk to a time point after the
rocedure has been completed.
essing Hard and Soft Clinical End Points
C-Statistic Soft End Point (Follow-Up) C-Statistic
0.91 Procedural failure (In-hospital) 0.56
l) 0.78 Angiographic success (In-hospital) 0.67
0.76 Cardiac death, MI, TLR (12 months) 0.64
0.83 Cardiac death, MI, TLR (12 months) 0.64
0.80 Death, stroke, MI, repeat revascularization (60 months) 0.67n Ass
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900Finally, data indicate that overall ability of clinical or
ngiographic models to predict hard end points (such as
ortality) is superior to their ability to predict softer
utcomes such as angiographic failure and repeat revas-
ularization. As shown in Table 8, this trend appears
onsistent with all risk models, with recent data from
arg et al. (52) indicating that combined scores such as
he CSS are not exempt from this phenomenon.
onclusions
here is a clear need for adequate risk stratification in
atients undergoing revascularization of the ULM. Al-
hough numerous different risk models are available for
he assessment of these patients, each has been evaluated
n a different patient population and has measured
ifferent outcome end points at varying follow-up time
eriods. This heterogeneity identifies an important gap in
he current evidence base. As a result, identification of a
ingle best risk score for use as a day-to-day clinical tool
s presently not possible. Assessment of prospectively and
arefully collected data from a large ULM population
ndergoing long-term follow-up is required to provide
he substrate from which a useful risk stratification model
an be developed that is capable of optimally discrimi-
ating between PCI and CABG in patients with ULM
isease requiring revascularization.
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